Radiopharm Theranostics (ASX: RAD) progresses trial targeting non-small cell lung cancer

January 24, 2024 12:11 PM AEDT | By Sonal Goyal
Follow us on Google News:


  • RAD is conducting RAD 204 Phase 1 therapeutic study that targets PDL1-positive non-small cell lung cancer.
  • The study will be conducted at the Princess Alexandra Hospital, Brisbane.
  • Recently, the company has expanded the geographic availability of the trial after receiving HREC approval.

Radiopharm Theranostics Limited (ASX: RAD) is an ASX-listed radiotherapeutics company  focused on developing a platform of innovative radiopharmaceutical products for therapeutic and diagnostic applications in the areas of unmet medical demand. One of the areas of unmet medical need that company targets is non-small lung cancer.

Under a research partnership with Australia’s Nuclear Science and Technology Organisation (ANSTO), the company has undertaken a trial comprising-

Under the trial, ANSTO would supply isotope non-carrier-added lutetium-177 (Lu-177) for research across Australia.

More about the Nanomab-PDL-1Phase 1 therapeutic trial

The title of the study is-

It is a first-in-human dose escalation trial of 177Lu-RAD 204, designed to assess the efficacy and safety of this radiotherapeutic in patients with advanced NSCLC.

At Princess Alexandra Hospital in Brisbane, the study will be conducted with the assistance of GenesisCare, an oncology care providing company.

Progress of the trial

On 22 December 2023, the company announced that the site initiation visit was finalised for the study. As of this date, pre-screening of eligible individuals was going on at the clinical site, projecting the commitment and readiness to dose patients with 177Lu-RAD 204.

On 27 December 2023, the Hollywood Private Hospital in Perth provided Human Research Ethics Committee (HREC) approval. With this approval, Hollywood Private Hospital will become second site for the trial in Australia. Addition of the Perth site is expected to boost the recruitment as the geographic availability of the study expands.

RAD shares traded at AU$0.075 apiece at the time of writing on 24 January 2024.



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.